Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Cytopathology : Official Journal of the British Society for Clinical Cytology|November 21, 2013
Histo-cytological diagnostic accuracy in lung cancerA Proietti, L Boldrini, G Alì, et al.
International Journal of Oncology|December 18, 2001
Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancerL Boldrini, P Faviana, S Gisfredi, et al.
Oncogene|October 20, 2001
Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancerL Boldrini, P Faviana, F Pistolesi, et al.
International Journal of Oncology|August 9, 2002
Evaluation of telomerase mRNA (hTERT) in colon cancerL Boldrini, P Faviana, S Gisfredi, et al.
International Journal of Molecular Medicine|October 10, 2002
Evaluation of telomerase in the development and progression of colon cancerL Boldrini, P Faviana, S Gisfredi, et al.
AIDS (London, England)|June 1, 1996
Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic miceA Corallini, D Campioni, C Rossi, et al.
British Journal of Cancer|April 4, 2013
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatinM Tiseo, P Bordi, B Bortesi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survivalG Fontanini, M De Laurentiis, S Vignati, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2013
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerF Loupakis, C Cremolini, L Salvatore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)L Fornaro, S Lonardi, G Masi, et al.
Pageof 11